NOP56 and Ataxia: SCA36 accounted for 1.9% of ataxia cases in the French population and 6.3% in the Galician region of Spain.4,6 In East Asia, SCA36 accounted for between 0.6 and 1.6% of SCA.8,11 Genetic screening of SCA36 in patients with ataxia in other parts of Europe, including the UK, Greece, Germany and Portugal, failed to identify patients carrying the NOP56 expansion.16–18